Delta Financial Group, Inc. Eli Lilly & CO Transaction History

Delta Financial Group, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$592.2 - $792.28 $4,145 - $5,545	7 Added 0.1%	6,740 $5.24 Million
Q4 2023 Jan 18, 2024	SELL	$525.19 - $619.13 $46,216 - $54,483	-88 Reduced 1.29%	6,733 $3.93 Million
Q3 2023 Oct 31, 2023	BUY	$434.7 - $599.3 $2.97 Million - $4.09 Million	6,821 New	6,821 $3.66 Million
Q1 2023 Apr 25, 2023	BUY	$310.63 - $364.82 $35,722 - $41,954	115 Added 8.37%	1,489 $512,000
Q4 2022 Feb 13, 2023	BUY	$321.55 - $374.67 $441,809 - $514,796	1,374 New	1,374 $501,000

4,007

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $750B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Delta Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Delta Financial Group, Inc. with notifications on news.